H. Bryan Brewer

Bryan is a co-founder of HDL Therapeutics and is the Chief Scientific Officer of the company. He leads the clinical development program of the company. Bryan was previously a member of the Board of the National Cholesterol Education Program, which established treatment guidelines for patients with hyperlipidemia in the United States and has served on the editorial boards of several prestigious journals including Clinical Lipidology. Bryan’s research led to the elucidation of the first published sequences for the human plasma apolipoproteins, the initial determination of the metabolism of the plasma apolipoproteins in normal and hyperlipidemic individuals, as well as the identification of multiple gene defects leading to the genetic dyslipoproteinias. He has pioneered the use of transgenic mice and rabbits as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of atherosclerosis. Bryan has published more than 450 original manuscripts and 75 reviews and book chapters on the subjects of genetic dyslipoprotenias, lipoprotein metabolism, and atherosclerosis.

Bryan is a recipient of the JD Lane Investigator Award from the US Public Health Service, the Heinrich Wieland Prize from the Federal Republic of Germany and the Public Health Service Commendation Award, Meritorious & Service, Distinguished Service Medals from the NIH, George Lyman Duff Memorial Award Lecture, and the Robert I. Levy Award.

Bryan received his medical degree from Stanford University School of Medicine. He completed his internship and residency in internal medicine at Massachusetts General Hospital.